| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| empagliflozin bladder cancer | 1.54 | 1 | 6219 | 100 | 28 |
| empagliflozin | 1.8 | 0.3 | 4707 | 84 | 13 |
| bladder | 1.6 | 0.7 | 7657 | 41 | 7 |
| cancer | 0.77 | 1 | 4671 | 14 | 6 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| empagliflozin bladder cancer | 1 | 0.1 | 7631 | 81 |
| empagliflozin and bladder cancer risk | 0.91 | 0.5 | 1252 | 11 |
| empagliflozin and bladder cancer | 0.9 | 0.6 | 701 | 67 |
| dapagliflozin and bladder cancer | 0.34 | 0.1 | 358 | 98 |
| empagliflozin urinary tract infection | 1.89 | 1 | 1778 | 25 |
| empagliflozin and kidney disease | 0.25 | 0.7 | 2998 | 45 |
| benefits and risks of empagliflozin | 0.65 | 0.4 | 1160 | 46 |
| pembrolizumab and bladder cancer | 1.36 | 1 | 4051 | 94 |
| gliclazide and empagliflozin together | 1.2 | 0.9 | 2688 | 9 |
| empagliflozin and sugar in urine | 0.4 | 0.5 | 8153 | 31 |
| empagliflozin and yeast infection | 1.27 | 1 | 154 | 29 |
| empagliflozin and gliclazide combination | 1.18 | 0.9 | 3655 | 82 |
| canagliflozin dapagliflozin and empagliflozin | 0.21 | 0.3 | 6805 | 62 |
